The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma
Open Access
- 6 November 2025
- journal article
- Published by Elsevier in Journal of Advanced Research
- Vol. 86, 543-557
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China
- Key Technologies Research and Development Program (2021YFA1201102)
This publication has 52 references indexed in Scilit:
- A membrane-associated MHC-I inhibitory axis for cancer immune evasionCell, 2023
- Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathwayBiochemical Pharmacology, 2022
- Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitorClinical & Translational Immunology, 2022
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in CancerCancer Cell, 2019
- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal CancerCancer Cell, 2019
- Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillanceImmunogenetics, 2019
- Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR ActivationCancer Cell, 2018
- Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4Cancer Letters, 2016
- Projections of cancer incidence and cancer‐related deaths in Germany by 2020 and 2030Cancer Medicine, 2016
- The PRMT5 arginine methyltransferase: many roles in development, cancer and beyondCellular and Molecular Life Sciences, 2015